 Urologic Neoplasms
"Urologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the URINARY TRACT in either the male or the female.
| Descriptor ID |
D014571
|
| MeSH Number(s) |
C04.588.945.947 C12.758.820 C13.351.937.820
|
| Concept/Terms |
Urologic Neoplasms- Urologic Neoplasms
- Urinary Tract Neoplasms
- Neoplasm, Urinary Tract
- Neoplasms, Urinary Tract
- Tract Neoplasm, Urinary
- Tract Neoplasms, Urinary
- Urinary Tract Neoplasm
- Urological Neoplasms
- Neoplasm, Urological
- Neoplasms, Urological
- Urological Neoplasm
- Neoplasms, Urologic
- Neoplasm, Urologic
- Urologic Neoplasm
Cancer of Urinary Tract- Cancer of Urinary Tract
- Urinary Tract Cancers
- Urological Cancer
- Cancer, Urological
- Cancers, Urological
- Urological Cancers
- Cancer of the Urinary Tract
- Urinary Tract Cancer
- Cancer, Urinary Tract
- Cancers, Urinary Tract
- Urologic Cancer
- Cancer, Urologic
- Cancers, Urologic
- Urologic Cancers
|
Below are MeSH descriptors whose meaning is more general than "Urologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Urologic Neoplasms".
This graph shows the total number of publications written about "Urologic Neoplasms" by people in this website by year, and whether "Urologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 2000 | 3 | 0 | 3 | | 2006 | 1 | 2 | 3 | | 2007 | 1 | 0 | 1 | | 2008 | 4 | 0 | 4 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 0 | 3 | | 2017 | 4 | 1 | 5 | | 2018 | 4 | 0 | 4 | | 2019 | 5 | 0 | 5 | | 2020 | 7 | 1 | 8 | | 2021 | 4 | 0 | 4 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Urologic Neoplasms" by people in Profiles.
-
Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232.
-
Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat S, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol. 2021 Jul 01; 28(4):179-195.
-
Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat SF, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol. 2021 07 01; 28(4):196-208.
-
Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
-
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
-
Darrell CM, Montironi R, Paner GP. Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. Expert Rev Mol Diagn. 2020 09; 20(9):921-932.
-
Paner GP, Montironi R. Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79:82-104: Importance of Standardized Pathology Reporting for Urological Cancers in the Implementation of Urology Guidelines. Eur Urol. 2021 01; 79(1):e30-e32.
-
Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020 10 15; 126(20):4485-4497.
-
Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, Lee S, Alarcon SV, Yuno A, Dawson NA, Allette K, Roy A, De Silva D, Lee MM, Sissung TM, Figg WD, Agarwal PK, Wright JJ, Ning YM, Gulley JL, Dahut WL, Bottaro DP, Trepel JB. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020 08; 21(8):1099-1109.
-
Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020 08 10; 38(23):2658-2666.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|